Philip R. O. Payne

Zehao Dong, Heming Zhang, Yixin Chen et al.

Synergistic drug combinations provide huge potentials to enhance therapeutic efficacy and to reduce adverse reactions. However, effective and synergistic drug combination prediction remains an open question because of the unknown causal disease signaling pathways. Though various deep learning (AI) models have been proposed to quantitatively predict the synergism of drug combinations, the major limitation of existing deep learning methods is that they are inherently not interpretable, which makes the conclusions of AI models untransparent to human experts, henceforth limiting the robustness of the model conclusion and the implementation ability of these models in real-world human--AI healthcare. In this paper, we develop an interpretable graph neural network (GNN) that reveals the underlying essential therapeutic targets and the mechanism of the synergy (MoS) by mining the sub-molecular network of great importance. The key point of the interpretable GNN prediction model is a novel graph pooling layer, a self-attention-based node and edge pool (henceforth SANEpool), that can compute the attention score (importance) of genes and connections based on the genomic features and topology. As such, the proposed GNN model provides a systematic way to predict and interpret the drug combination synergism based on the detected crucial sub-molecular network. Experiments on various well-adopted drug-synergy-prediction datasets demonstrate that (1) the SANEpool model has superior predictive ability to generate accurate synergy score prediction, and (2) the sub-molecular networks detected by the SANEpool are self-explainable and salient for identifying synergistic drug combinations.

Zehao Dong, Qihang Zhao, Philip R. O. Payne et al.

Biomarker identification is critical for precise disease diagnosis and understanding disease pathogenesis in omics data analysis, like using fold change and regression analysis. Graph neural networks (GNNs) have been the dominant deep learning model for analyzing graph-structured data. However, we found two major limitations of existing GNNs in omics data analysis, i.e., limited-prediction (diagnosis) accuracy and limited-reproducible biomarker identification capacity across multiple datasets. The root of the challenges is the unique graph structure of biological signaling pathways, which consists of a large number of targets and intensive and complex signaling interactions among these targets. To resolve these two challenges, in this study, we presented a novel GNN model architecture, named PathFormer, which systematically integrate signaling network, priori knowledge and omics data to rank biomarkers and predict disease diagnosis. In the comparison results, PathFormer outperformed existing GNN models significantly in terms of highly accurate prediction capability ( 30% accuracy improvement in disease diagnosis compared with existing GNN models) and high reproducibility of biomarker ranking across different datasets. The improvement was confirmed using two independent Alzheimer's Disease (AD) and cancer transcriptomic datasets. The PathFormer model can be directly applied to other omics data analysis studies.

Zehao Dong, Muhan Zhang, Philip R. O. Payne et al.

The expressivity of Graph Neural Networks (GNNs) has been studied broadly in recent years to reveal the design principles for more powerful GNNs. Graph canonization is known as a typical approach to distinguish non-isomorphic graphs, yet rarely adopted when developing expressive GNNs. This paper proposes to maximize the expressivity of GNNs by graph canonization, then the power of such GNNs is studies from the perspective of model stability. A stable GNN will map similar graphs to close graph representations in the vectorial space, and the stability of GNNs is critical to generalize their performance to unseen graphs. We theoretically reveal the trade-off of expressivity and stability in graph-canonization-enhanced GNNs. Then we introduce a notion of universal graph canonization as the general solution to address the trade-off and characterize a widely applicable sufficient condition to solve the universal graph canonization. A comprehensive set of experiments demonstrates the effectiveness of the proposed method. In many popular graph benchmark datasets, graph canonization successfully enhances GNNs and provides highly competitive performance, indicating the capability and great potential of proposed method in general graph representation learning. In graph datasets where the sufficient condition holds, GNNs enhanced by universal graph canonization consistently outperform GNN baselines and successfully improve the SOTA performance up to $31\%$, providing the optimal solution to numerous challenging real-world graph analytical tasks like gene network representation learning in bioinformatics.

Sayantan Kumar, Sean C. Yu, Thomas Kannampallil et al.

Complex deep learning models show high prediction tasks in various clinical prediction tasks but their inherent complexity makes it more challenging to explain model predictions for clinicians and healthcare providers. Existing research on explainability of deep learning models in healthcare have two major limitations: using post-hoc explanations and using raw clinical variables as units of explanation, both of which are often difficult for human interpretation. In this work, we designed a self-explaining deep learning framework using the expert-knowledge driven clinical concepts or intermediate features as units of explanation. The self-explaining nature of our proposed model comes from generating both explanations and predictions within the same architectural framework via joint training. We tested our proposed approach on a publicly available Electronic Health Records (EHR) dataset for predicting patient mortality in the ICU. In order to analyze the performance-interpretability trade-off, we compared our proposed model with a baseline having the same set-up but without the explanation components. Experimental results suggest that adding explainability components to a deep learning framework does not impact prediction performance and the explanations generated by the model can provide insights to the clinicians to understand the possible reasons behind patient mortality.

Tianyu Zhang, Liwei Zhang, Philip R. O. Payne et al.

Drug resistance is still a major challenge in cancer therapy. Drug combination is expected to overcome drug resistance. However, the number of possible drug combinations is enormous, and thus it is infeasible to experimentally screen all effective drug combinations considering the limited resources. Therefore, computational models to predict and prioritize effective drug combinations is important for combinatory therapy discovery in cancer. In this study, we proposed a novel deep learning model, AuDNNsynergy, to prediction drug combinations by integrating multi-omics data and chemical structure data. In specific, three autoencoders were trained using the gene expression, copy number and genetic mutation data of all tumor samples from The Cancer Genome Atlas. Then the physicochemical properties of drugs combined with the output of the three autoencoders, characterizing the individual cancer cell-lines, were used as the input of a deep neural network that predicts the synergy value of given pair-wise drug combinations against the specific cancer cell-lines. The comparison results showed the proposed AuDNNsynergy model outperforms four state-of-art approaches, namely DeepSynergy, Gradient Boosting Machines, Random Forests, and Elastic Nets. Moreover, we conducted the interpretation analysis of the deep learning model to investigate potential vital genetic predictors and the underlying mechanism of synergistic drug combinations on specific cancer cell-lines.